, Volume 48, Issue 6, pp 888–893 | Cite as

Botulinum Toxin in Clinical Practice

  • Andrew J. Hughes
Practical Therapeutics


Over recent years botulinum toxin type A has emerged as a safe and effective treatment for a number of previously refractory conditions associated with excessive muscle activity. The list of indications is expanding, but at present it is generally considered to be the treatment of choice for focal dystonias such as blepharospasm, torticollis, laryngeal dystonia, and oromandibular dystonia, as well as hemifacial spasm, strabismus, and some forms of limb spasticity. Carefully targeted intramuscular injections of a small amount of the toxin block the release of acetylcholine at the neuromuscular junction, producing a chemical denervation, with the aim of reducing excessive muscle activity without producing significant functional weakness. In some situations electrophysiological assessment and localisation of the muscles for injection is necessary.

Treatment is symptomatic, with effects lasting 3 to 4 months and most patients requiring up to 4 injections per year to maintain the beneficial effect. Appropriate use of the toxin requires both an understanding of the physiological action of the potential muscles involved in each situation, together with a knowledge of the likely dose necessary to reduce muscle activity to the required level. Botulinum toxin represents a major advance in the management of these conditions, many of which responded poorly to previously available forms of therapy.


Dystonia Botulinum Toxin Achalasia Cervical Dystonia Botulinum Toxin Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Therapeutics and Technology Subcommittee of the American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin A in treating neurologic disorders. Neurology 1990; 40: 1332–6CrossRefGoogle Scholar
  2. 2.
    Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186–94PubMedCrossRefGoogle Scholar
  3. 3.
    Scott AB. Botulinum toxin injections into extra ocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044–9PubMedGoogle Scholar
  4. 4.
    Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 1992; 239: 16–20PubMedCrossRefGoogle Scholar
  5. 5.
    Quinn N, Hallet M. Dose standardisation of botulinum toxin. Lancet 1989; 1: 964PubMedCrossRefGoogle Scholar
  6. 6.
    Cornelia CL, Buchman AS, Tanner CM, et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992; 42: 878–82CrossRefGoogle Scholar
  7. 7.
    Lange DJ, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987; 10: 552–5PubMedCrossRefGoogle Scholar
  8. 8.
    Eiston J. Botulinum toxin treatment of blepharospasm. Adv Neurol 1988; 50: 579–81Google Scholar
  9. 9.
    Stell R, Thompson PD, Marsden CD. Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1988; 51: 920–3PubMedCrossRefGoogle Scholar
  10. 10.
    Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990; 40: 277–80PubMedCrossRefGoogle Scholar
  11. 11.
    Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992; 326: 349–50PubMedCrossRefGoogle Scholar
  12. 12.
    Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991; 100: 85–9PubMedGoogle Scholar
  13. 13.
    Lees AJ. Botulinum toxin: useful in adult onset focal dystonias. BMJ 1992; 305: 1169–70PubMedCrossRefGoogle Scholar
  14. 14.
    Brin MF, Fahn S, Moskowitz C, et al. Localised injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987; 2: 237–54PubMedCrossRefGoogle Scholar
  15. 15.
    Jankovic J, Schwartz PA. Botulinum toxin treatment of tremors. Neurology 1991; 41: 1185–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Andrew J. Hughes
    • 1
  1. 1.Repatriation and Austin HospitalsHeidelbergAustralia

Personalised recommendations